AU2024219970A1 — Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
Assigned to Opus Genetics Inc · Expires 2024-10-10 · 2y expired
What this patent protects
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phento-lamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders. See Fig. …
USPTO Abstract
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phento-lamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders. See Fig. 1. WO 2020/087021 PCT/US2019/058182 1/3 --------------------------------- JJ 0 0 ..... ... CO .. .... .. .. .. .. LLJ 0 CO CIID~rrrTECUEE iDII0
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.